Peginesatide

Peginesatide (Omontys) is a real, FDA-approved-then-withdrawn PEGylated peptide drug — a genuine market-withdrawal case study, pulled from sale less than a year after launch following fatal anaphylaxis reports, and a useful reminder that FDA approval is not a permanent guarantee of safety.

What it was, and why it was approved

Peginesatide was a synthetic, PEGylated peptide that bound and activated the erythropoietin receptor (EPO-R) to treat anemia in dialysis patients — not derived from erythropoietin's own amino acid sequence, but engineered to hit the same receptor, with a PEG chain extending its half-life enough to allow once-monthly dosing instead of the weekly-to-thrice-weekly schedule older erythropoiesis-stimulating agents required. The FDA approved it on 27 March 2012, specifically for anemia due to chronic kidney disease in adults on dialysis — not for non-dialysis CKD anemia, a distinction that matters below.

The withdrawal timeline

On 23 February 2013 — under 11 months after launch, with more than 25,000 patients already treated — Affymax and Takeda announced a nationwide recall of all lots of Omontys, in agreement with the FDA, after postmarketing reports of serious hypersensitivity reactions including anaphylaxis, some fatal, typically occurring within 30 minutes of dosing and often after the very first dose. Reported figures at the time: fatal reactions in roughly 0.02% of patients following their first IV dose, and overall hypersensitivity reactions in about 0.2% of patients. Takeda formally began withdrawing the NDA in June 2014, and the FDA published the final Federal Register notice withdrawing approval of Omontys on 13 February 2019 — closing the file for good.

What the trials had already shown

The pivotal trials, both published in NEJM in January 2013 — after approval — told a more complicated story than the approval alone suggested. EMERALD 1/2 (Fishbane et al., PMID 23343061) found peginesatide non-inferior to epoetin in dialysis patients, the approved population. But PEARL (Macdougall et al., PMID 23343062), testing peginesatide in non-dialysis CKD patients — the population it was never approved for — found similar anemia efficacy to darbepoetin but a numerically higher rate of cardiovascular events and death with peginesatide. That signal, in an unapproved population, sat alongside the drug's eventual real-world safety failure in its approved population.

Why this case study matters

Peginesatide is a useful, honest reminder for a site that spends most of its time distinguishing "approved" from "unapproved": approval is a real regulatory bar, but it is not a permanent guarantee, and this drug is a genuine example of the post-market surveillance system working as intended — real-world adverse events surfaced quickly, the manufacturer and FDA acted within roughly a year, and the drug has not returned to market since.